# A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662

> **NCT02194491** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Pharmacokinetics of ASP3662
- Displacement of Radiotracer
- Healthy Volunteers

## Interventions

- **OTHER:** [11C]AS2471907
- **RADIATION:** Positron Emission Tomography (PET)
- **DRUG:** ASP3662

## Key facts

- **NCT ID:** NCT02194491
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2016-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02194491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02194491, "A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02194491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*